Zoonotic diseases in animal agriculture and beyond: a one health perspective

This publication focuses on a group of vignettes to help understand zoonotic diseases, the anthropogenic factors accelerating their emergence, and the consequences of these events. While human activities and behavior are mostly responsible for creating this new era, the world struggles to prepare, change behavior, and rethink strategies to effectively address the inevitability of more frequent occurrences and severity of disease outbreaks and pandemics. Although we know and have experienced the cost of failure, past disease outbreaks seem to be quickly lost from our collective memories and new innovative interventions have not been imagined or adopted. This publication highlights examples that challenge our traditional actions and thinking and emphasize the need to adopt new approaches to prevent or ameliorate zoonotic diseases. The consensus of the experts contributing to this publication is that One Health should be embraced to achieve these results. The growing costs and societal disruptions of outbreaks and pandemics demand that zoonoses be part of our national security planning and deserve commensurate investments in preparedness, prevention, research, and resilience. This publication also highlights the necessity to fundamentally rethink and reestablish new relationships among institutions, organizations, and countries and especially between humanity and our natural systems worldwide.

Feral American mink Neogale vison continues to expand its European range: time to harmonise population monitoring and coordinate control

The American mink Neogale vison is an invasive alien species in Europe that threatens endemic biodiversity and can transmit zoonotic diseases, including the SARS-CoV-2 virus. The last attempt to map the geographic range of this species in Europe, at continental scale, dates back to 2007. We aimed to update the distribution map of the feral American mink and assess its temporal trends. The information we collected was critically analysed with the aim of improving future monitoring protocols and data collection. We gathered and standardised data from 34 databases, covering 32 countries. Through 3 five-year periods from 2007 to 2021, changes in range size, hunting bags and capture statistics were analysed. We also reviewed the current situation of mink farming in the different European countries and recorded population control schemes. The American mink is now widespread in the Baltic States, France, Germany, Iceland, Ireland, Poland, Scandinavia, Spain and the UK. The species is reported to be absent in some areas (e.g. parts of the UK, Iceland and Norway). Data are deficient for several countries, mainly in south-eastern Europe. These findings indicate that, during the last 15 years, the species has continued to spread across the continent, increasing its potential extent of occurrence in most countries. Our effort to collect and harmonise data across international borders highlighted information gaps and heterogeneity in data quality. Updated distribution data on the species provided here will aid risk assessment and risk management policies. These actions require a coordinated effort for population monitoring at continental level. Monitoring effort and data collection should be intensified in south-eastern Europe to improve data on the current distribution of this invasive species. © 2023 The Authors. Mammal Review published by Mammal Society and John Wiley & Sons Ltd.

Cardiopulmonary Exercise Performance in the Pediatric and Young Adult Population Before and During the COVID-19 Pandemic.

Physical activity (PA) decreased and sedentary behavior (SB) increased in the pediatric population during the Coronavirus Disease 2019 (COVID-19) pandemic. We examined the effects of PA and SB on cardiopulmonary exercise performance in children, adolescents and young adults both with and without underling cardiac disease, and hypothesized that there will be a change in aerobic and physical working capacity during the pandemic. This was a single-center retrospective longitudinal cohort study in patients age 6-22 years who underwent serial maximal cardiopulmonary exercise stress testing before and during the COVID-19 pandemic. Metabolic variables were obtained; PA and SB data were extracted from clinic notes. A total of 122 patients (60% male) underwent serial exercise testing with a median age of 14 years at the first CPET. Predicted peak aerobic capacity significantly decreased among both females and males during the pandemic, even after adjusting for changes in somatic growth. There was no significant change in physical working capacity during the pandemic. Patients who were more aerobically fit experienced a greater decrease in aerobic capacity during the pandemic compared to those less fit. In conclusion, cardiopulmonary exercise performance, notably aerobic activity, decreased during the COVID-19 pandemic in children, adolescents and young adults compared to pre-pandemic values. This decline was most notable in those with the highest pre-pandemic aerobic capacity values and was independent of somatic growth or changes in BMI. This study has public health implications and demonstrates the importance of PA on overall cardiovascular health.

Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC)

Background: Paclitaxel is commonly used as first line chemotherapy for HER2 negative MBC. However, with response rates of 21.5-53.7% and a significant risk of peripheral neuropathy there is a need for more effective and better tolerated chemotherapy (CCT). Methods: This open label randomised (1:1) phase 2 trial compared 6 cycles of cabazitaxel (25 mg/m2 ) every 3 weeks, with weekly paclitaxel (80mg/m2 ) over 18 weeks as first line CCT. HER2 negative and performance status ≤1 patients were eligible. Patients on cabazitaxel received GCSF prophylaxis. Primary endpoint was Progression Free Survival (PFS) with 127 events required to detect a hazard ratio (HR) of 0.65 with 85% power. Secondary endpoints included objective response rate (ORR;RECIST 1.1), time to response (TTR), overall survival (OS), safety and tolerability and quality of life (QoL). Results: 158 patients were recruited from 14 UK hospitals (79 in each arm). Median age (range) was 56(34-81) in the cabazitaxel arm and 61(34-79) in the paclitaxel arm. 61% of patients were performance status 0. Median time on treatment was 15 weeks for both arms, but more patients on paclitaxel had a treatment delay (61% vs 39%) or dose reduction (37% vs 24%). Comparing cabazitaxel to paclitaxel after 146 PFS events, median PFS was 6.7 vs 5.8 months (HR 0.84;95%CI 0.60-1.18, P = 0.3). There was no difference in OS, median 19.3 vs 20.0 months (HR 0.94;95%CI 0.63-1.40, P = 0.7), ORR (42% vs 37%) or TTR (HR 1.09;95%CI 0.68- 1.74, P = 0.7). Grade ≥3 adverse events occurred in 42% of patients on cabazitaxel and 48% on paclitaxel. Diarrhoea, febrile neutropenia and nausea were the most common grade ≥3 events in the cabazitaxel arm with rates of 11%, 11% and 10% respectively compared to 1%, 1% and 0% in the paclitaxel arm. In the paclitaxel arm the top grade ≥3 events were lung infection and peripheral neuropathy, 6% and 5% respectively compared to 2.5% and 0% in the cabazitaxel arm. Peripheral neuropathy of any grade was reported by 55% of patients treated with paclitaxel vs 17% on cabazitaxel. Alopecia occurred in 41% of patients on paclitaxel compared to 27% on cabazitaxel. Adverse events leading to discontinuation were more frequent with paclitaxel (22%) than cabazitaxel (14%). Over the course of treatment, mean EQ5D single index utility score (+0.05;95%CI 0.004-0.09, P = 0.03) and visual analogue scale score (+7.7;95%CI 3.1-12.3, P = 0.001) were higher in the cabazitaxel arm compared to paclitaxel suggestive of better QoL on Cabazitaxel. Conclusions: 3 weekly cabazitaxel as first line chemotherapy in HER2 negative MBC does not significantly improve PFS compared to weekly paclitaxel, though it has a lower risk of peripheral neuropathy with better patient reported overall health outcomes. Cabazitaxel is safe and well tolerated for MBC and requires fewer hospital visits, an important consideration in the COVID pandemic and beyond.